	US 12,133,882 B2
	Neuregulin based methods for treating heart failure
Mingdong Zhou, Shanghai (CN)
Assigned to Zensun (Shanghai) Science & Technology, Co., Ltd., Shanghai (CN)
Filed by Zensun (Shanghai) Science & Technology, Co., Ltd., Shanghai (CN)
Filed on Jan. 18, 2022, as Appl. No. 17/578,147.
Application 17/578,147 is a division of application No. 15/601,856, filed on May 22, 2017, granted, now 11,246,909.
Application 15/601,856 is a continuation of application No. 14/746,717, filed on Jun. 22, 2015, granted, now 9,655,949, issued on May 23, 2017.
Application 14/746,717 is a continuation of application No. 13/376,865, granted, now 9,089,524, issued on Jul. 28, 2015, previously published as PCT/CN2010/000845, filed on Jun. 12, 2010.
Claims priority of provisional application 61/236,849, filed on Aug. 25, 2009.
Prior Publication US 2022/0133855 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); G06V 40/13 (2022.01); H10N 39/00 (2023.01)

CPC A61K 38/1883 (2013.01) [A61K 38/1808 (2013.01); G06V 40/1306 (2022.01); H10N 39/00 (2023.02)]

12 Claims

1. A method for treating heart failure in mammals in need thereof, which method comprises administering to the mammal in need thereof a neuregulin 1 protein in an amount:

a) from about 0.3 μg to about 2.4 μg/kg/day;

b) from about 6 EU to about 48 EU/kg/day; or

c) from about 0.04 nmol to about 0.34 nmol/kg/day.